Online inquiry

IVTScrip™ mRNA-Anti-GHR, HM10560A(Cap 0, 5-Methyl-CTP, 30 nt-poly(A))   (CAT#: GTTS-WQ8285MR)

This product GTTS-WQ8285MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets GHR gene. The antibody can be applied in Growth hormone (GH) deficiency research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_000163.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2690
UniProt ID P10912
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-GHR, HM10560A(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) (GTTS-WQ8285MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ9517MR IVTScrip™ mRNA-Anti-FOLH1, J-591(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA J-591
GTTS-WQ3294MR IVTScrip™ mRNA-Anti-alpha toxin&<br />lukE, ASN-1(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA ASN-1
GTTS-WQ15291MR IVTScrip™ mRNA-Anti-EGFR, Theraloc(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA Theraloc
GTTS-WQ6393MR IVTScrip™ mRNA-Anti-Factor IX substitute, CSL654(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA CSL654
GTTS-WQ10753MR IVTScrip™ mRNA-Anti-ADAMTSL5&ALB, M-6495(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA M-6495
GTTS-WQ11588MR IVTScrip™ mRNA-Anti-ERBB2, MGAH-22(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA MGAH-22
GTTS-WQ174MR IVTScrip™ mRNA-Anti-EGFR, 1-26/3-67(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA 1-26/3-67
GTTS-WQ11806MR IVTScrip™ mRNA-Anti-PDCD1, MK-3475(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA MK-3475
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW